Jeena Sikho (JSLL)

Fast Grower

FairStock Score: 50/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹521.35
Market Cap₹6,480.42 Cr
P/E Ratio27.47
ROCE50.24%
ROE—%
Dividend Yield0.21%
Profit Growth28.4%
Debt/Equity0.27
Sales Growth28.8%
Promoter Holding63.62%
52-Week Range₹491.95 — ₹849.5
SectorPharmaceuticals & Biotechnology
Book Value₹37.57

Strengths

Concerns

AI Analysis

At first glance, Jeena Sikho looks like the kind of growth story that gets investors excited. Sales up 91.6%, profit up 405%, latest quarter ₹222 Cr sales and ₹67 Cr profit. ROCE of 50.24% is exceptional, and debt/equity of 0.30 is conservative. Piotroski F-score of 7 out of 9 tells me the underlying financials are reasonably healthy. Promoters hold 63.62%, so their interests are aligned with mine. Yet I must stop and apply the Graham test. A P/E of 37.05 and P/B of 23.23 against book value of ₹28.47 means I'm paying a steep price for every rupee of earnings and assets. The PEG of 0.15 assumes this extraordinary growth is durable; but profit growth of 405% is mathematically unsustainable. As Graham liked to say, 'The future is never clear; you pay a high price for a cheery consensus.' The dividend yield is only 0.18%, so I'm not being paid while I wait. FairStock Score of 53/100 flags a mixed picture. I would rather be late to a wonderful business at a fair price than early to an overpriced lottery ticket. If the company can keep compounding at a high rate, today's price may eventually look reasonable, but I need a margin of safety. That margin is missing at 37 times earnings. I'd put Jeena Sikho on my watchlist, but I won't chase it here.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer